Santa Clara Convention Center
April 11 @ 10:16 pm
Avid Bioservices Announces Grand Opening of New Early-Phase Center of Excellence Facility. Read the Release
Avid Bioservices Announces Grand Opening of New Early-Phase Center of Excellence Facility. Read the Release
Santa Clara Convention Center
April 11 @ 10:16 pm
Press Release: Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California Costa Mesa, Calif. – [February 24, 2026] – Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state of the art 78,000 square foot facility located in Costa Mesa, California. Purpose built to support early clinical […]
Read moreSeasoned business and finance leader brings growth mindset to support Avid’s next phase expansion and client execution TUSTIN, Calif. — [January 15, 2026] — Avid Bioservices, a leading contract development and manufacturing organization (CDMO) providing process development and CGMP manufacturing services for biopharmaceutical products, today announced the appointment of Rich McAvoy as Chief Business Officer (CBO). […]
Read moreThe newly created role marks a major step in CEO Kenneth Bilenberg’s vision to scale Avid for its next chapter of growth. TUSTIN, Calif., November 10, 2025 – Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dave Stewart as Chief Technology and Transformation Officer, a […]
Read moreTustin, CA, USA – September 15, 2025 – Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new Chief Executive Officer (CEO). A seasoned industry executive with more than 20 years of experience, Bilenberg most recently served as Chief Operating Officer of Fujifilm […]
Read moreSOUTH SAN FRANCISCO, California – August 05, 2025 – Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for up to $10.4 million for developing high productivity Chinese hamster ovary cell lines for manufacturing filovirus monoclonal antibodies for therapeutic […]
Read more